

セグメント別売上概況 Net Sales by Business Segment

※=前年同期比/YoY

		Q3 Mar. 2014			Q3 Mar. 2015					
		JPN	INTL	WW	JPN	%	INTL	%	WW	%
IS	Interventional Systems	27,114	76,585	103,700	25,896	-4.5%	87,347	14.1%	113,244	9.2%
ニューロバスキュラー	Neurovascular	1,351	10,615	11,966	1,694	25.3%	12,422	17.0%	14,117	18.0%
CV	Cardiovascular Systems	6,752	21,893	28,646	6,911	2.4%	24,214	10.6%	31,125	8.7%
血管	Vascular Graft	1,550	6,975	8,526	1,495	-3.5%	8,058	15.5%	9,553	12.1%
心臓血管カンパニー	Cardiac & Vascular Company	36,769	116,070	152,839	35,997	-2.1%	132,043	13.8%	168,041	9.9%
基盤医療器	General Hospital Products	37,959	22,893	60,853	37,241	-1.9%	22,106	-3.4%	59,347	-2.5%
医薬品・栄養	Pharmaceutical and Nutrition	28,849	3	28,853	27,174	-5.8%	-	-100.0%	27,174	-5.8%
D&D	Drug & Device	12,878	3,114	15,993	13,605	5.6%	3,931	26.2%	17,536	9.7%
DM・ヘルスケア	DM and Consumer Healthcare	15,946	2,266	18,212	15,695	-1.6%	2,712	19.7%	18,407	1.1%
ホスピタルカンパニー	General Hospital Company	95,634	28,277	123,911	93,716	-2.0%	28,749	1.7%	122,466	-1.2%
血液システムカンパニー	Blood Management Company	9,707	58,833	68,541	9,207	-5.2%	63,486	7.9%	72,693	6.1%
調整額	Adjustment	-1	-30	-31	-	-	-	-	-	-
計	Total	142,110	203,150	345,260	138,922	-2.2%	224,278	10.4%	363,201	5.2%

(期中平均為替レート)

Average exchange rate

(US\$1=¥99.36)

(US\$1=¥106.73)

(EUR1=¥132.17)

(EUR1=¥140.21)

※従来、心臓血管カンパニーに含まれていたハーベステクノロジーズ社については、2015年3月期第3四半期より血液システムカンパニーに含めております。

四半期別推移 Quarterly History for the Income Statement

		Q1	Q2	Q3	Q4	Mar. 2014	Q1	Q2	Q3	Mar. 2015
		Mar. 2014	Mar. 2014	Mar. 2014	Mar. 2014		Mar. 2015	Mar. 2015	Mar. 2015	Forecast
売上高	Net Sales	111,090	114,938	119,232	122,099	467,359	114,945	118,364	129,891	488,000
	各四半期売上高/年間売上高	23.8%	24.6%	25.5%	26.1%	100.0%	23.6%	24.3%	26.6%	100.0%
売上総利益	Gross Profit	56,990	60,155	61,514	63,350	242,011	60,706	62,232	67,739	
	%Net Sale	51.3%	52.3%	51.6%	51.9%	51.8%	52.8%	52.6%	52.2%	
販売管理費	SG&A Expenses	43,661	43,014	43,732	46,313	176,722	44,591	45,356	47,860	
	%Net Sale	39.3%	37.4%	36.7%	37.9%	37.8%	38.8%	38.3%	36.8%	
営業利益	Operating Income	13,329	17,140	17,781	17,037	65,288	16,114	16,875	19,878	64,000
	%Net Sale	12.0%	14.9%	14.9%	14.0%	14.0%	14.0%	14.3%	15.3%	13.1%
経常利益	Ordinary Income	12,940	16,628	20,350	13,882	63,802	14,449	19,589	24,649	62,000
	%Net Sale	11.6%	14.5%	17.1%	11.4%	13.7%	12.6%	16.6%	19.0%	12.7%
当期純利益	Net Income	8,956	10,502	17,437	-2,800	34,096	8,394	13,485	11,546	33,500
	%Net Sale	8.1%	9.1%	14.6%	-2.3%	7.3%	7.3%	11.4%	8.9%	6.9%

キャッシュ・フロー計算書(要約) Statements of Cash Flows

		Q3	Q3
		Mar. 2014	Mar. 2015
営業キャッシュ・フロー	Net Cash Provided by (Used in) Operating Activities	64,757	42,409
投資キャッシュ・フロー	Net Cash Provided by (Used in) Investing Activities	Δ37,878	Δ122,096
フリーキャッシュ・フロー	Free Cash Flow	26,879	Δ79,687
財務キャッシュ・フロー	Net Cash Provided by (Used in) Financing Activities	Δ17,262	92,088
現金同等物の換算差額	Effect of exchange rate change on cash and cash equivalents	6,836	10,923
現金及び現金同等物の増減	Net increase (decrease) in cash and cash equivalents	16,453	23,324
現金及び現金同等物の期首残高	Cash and cash equivalents at beginning of period	75,165	92,498
現金及び現金同等物の四半期末残高	Cash and cash equivalents at end of period	91,618	115,822

参考情報 Additional Information

		Q3	Q3	Mar. 2015
		Mar. 2014	Mar. 2015	Forecast
研究開発費	Research and Development	22,421	20,949	31,000
設備投資額	Capital Expenditure	40,432	30,778	42,000
減価償却費	Depreciation and Amortization	29,278	30,075	41,000